Kusuzaki K, Takeshita H, Murata H, Hirata M, Hashiguchi S, Ashihara T, Hirasawa Y
Department of Orthopaedic Surgery, Kyoto Prefectural University of Medicine, Hirokoji, Japan.
Cancer. 1998 Jun 15;82(12):2343-9. doi: 10.1002/(sici)1097-0142(19980615)82:12<2343::aid-cncr7>3.0.co;2-t.
Although chemosensitivity to antiosteosarcoma agents is the most important prognostic factor in human osteosarcoma, none of the many chemosensitivity tests reported previously are reliable and clinically useful. In this study, the authors investigated the reliability and clinical availability of doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH) binding assay (ABA) as a new chemosensitivity test for osteosarcoma.
Doxorubicin (adriamycin [ADM]) binding ability (%AB) to nuclear DNA in isolated osteosarcoma cells was assessed by ABA in 14 patients with primary osteosarcoma who were treated with preoperative chemotherapy containing ADM and 6 patients with relapsed osteosarcoma after intensive chemotherapy. Histologic responses to preoperative chemotherapy were evaluated by percentage of tumor necrosis (%necrosis).
Four of the 14 patients with primary osteosarcoma had %AB > 80% (97.3+/-3.7%) and demonstrated good histologic responses (>90% of %necrosis) to preoperative chemotherapy, whereas the remaining 10 patients had %AB < 80% (38.9+/-21.0%) and demonstrated poor responses. Patients with recurrent osteosarcoma that was clinically evaluated to be resistant to previous chemotherapy also had low %AB (34.2+/-28.3%).
Because the results of the current study revealed that ABA is useful for predicting chemosensitivity to chemotherapy with ADM as well as chemotherapy without ADM for patients with osteosarcoma, and because ABA technically is simple and results can be assessed rapidly, the authors conclude that ABA is a clinically useful chemosensitivity test for patients with osteosarcoma.
尽管对抗骨肉瘤药物的化学敏感性是人类骨肉瘤最重要的预后因素，但此前报道的众多化学敏感性测试中，没有一个是可靠且具有临床实用性的。在本研究中，作者调查了阿霉素（阿霉素；阿德里亚实验室，俄亥俄州哥伦布市）结合测定法（ABA）作为一种新的骨肉瘤化学敏感性测试的可靠性和临床实用性。
通过ABA评估了14例接受含阿霉素术前化疗的原发性骨肉瘤患者和6例强化化疗后复发的骨肉瘤患者分离的骨肉瘤细胞中阿霉素（阿霉素[ADM]）与核DNA的结合能力（%AB）。通过肿瘤坏死百分比（%坏死）评估术前化疗的组织学反应。
14例原发性骨肉瘤患者中有4例%AB>80%（97.3±3.7%），对术前化疗表现出良好的组织学反应（%坏死>90%），而其余10例患者%AB<80%（38.9±21.0%），反应较差。临床评估对先前化疗耐药的复发性骨肉瘤患者的%AB也较低（34.2±28.3%）。
由于本研究结果表明ABA可用于预测骨肉瘤患者对含阿霉素化疗以及不含阿霉素化疗的化学敏感性，且由于ABA技术操作简单且结果可快速评估，作者得出结论，ABA是一种对骨肉瘤患者具有临床实用性的化学敏感性测试。
